Incidence, prevalence, risk factors and health consequences of polypharmacy in adults in South Asia: a systematic review protocol by Khan, Nusrat et al.
The JBI Database of Systematic Reviews and Implementation Reports 
Title Page 
 
Title: Incidence, prevalence, risk factors and health consequences of polypharmacy among 
adults in South Asia: a systematic review protocol 
 
  
 
Authors: 
Nusrat Khan1,2 
Kaushik Chattapadhay1,2 
Jo Leonardi Bee1,2 
 
 
 
 
1.Division of Epidemiology & Public Health, School of Medicine, University of 
Nottingham, Nottingham, United Kingdom 
 
2.The Nottingham Centre for Evidence-Based Healthcare: A Joanna Briggs 
Institute Centre of Excellence,  
 
 
 
 
 
Corresponding Author: Nusrat Khan 
           Nusrat.khan@brac.net 
 
 
 
Acknowledgement: 
 
The authors would like to thank Jane Grogan, a senior research librarian at the University of 
Nottingham (UK) for her contribution to the search strategy. 
 
Title  
Incidence, prevalence, risk factors and health consequences of polypharmacy among adults in South 
Asia: a systematic review protocol  
Review objectives and questions 
The objectives of this systematic review are to summarize the incidence, prevalence, risk factors and 
health consequences of polypharmacy among adults in South Asia (i.e., Afghanistan, Bangladesh, 
Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka).  
1) What is the incidence and prevalence of polypharmacy among adults in South Asia? 
2) What are the risk factors of polypharmacy among adults in South Asia? 
3) What are the health consequences of polypharmacy among adults in South Asia? 
Introduction 
The dual burden of diseases and multimorbidity  
The burden of infectious diseases and non-communicable diseases (NCDs) is known as the dual 
burden of diseases.1 The associated morbidity and mortality have a huge negative impact on the patient, 
their family/carer, the health system, and the economy. In developed countries, the burden of NCDs is 
high, which has been the case for the last few decades.2 In many developing countries, the burden has 
already shifted from infectious diseases to NCDs.1 According to the World Health Organization, in 2015, 
NCDs accounted for 70% of the total of 56.4 million deaths worldwide, and infectious diseases and 
other health conditions accounted for the rest.2-4  
Multimorbidity is defined as the coexistence of two or more chronic diseases in an individual. Similar to 
the dual burden of diseases, multimorbidity places a huge burden on the patient, their family/carer, the 
health system and the economy.5 Globally, the prevalence of multimorbidity is nearly eight percent.6 
The prevalence is also increasing in low and middle-income countries (LMICs).3 
Polypharmacy 
The concurrent use of multiple drugs is known as polypharmacy.7 A standardized universally accepted 
definition of polypharmacy is not available. A recently published systematic review reported that 
approximately half of the published studies defined polypharmacy as administering five or more 
medicines to an individual. They found a huge variation in the definition of polypharmacy used, which 
ranged from two or more medications to eleven or more medications.8 Globally, the prevalence of 
polypharmacy has almost doubled in the last twenty years and currently varies widely at country-level 
(7-90%),7-19 however, due to under-reporting, the true prevalence could be much higher. The number 
of drugs prescribed to an individual depends on a number of factors, such as their disease diagnosis, 
their functional status and life expectancy, their preferences and the healthcare infrastructure including 
the availability of medicines. With the rise in multimorbidity and aging population, the trend of prescribing 
multiple drugs is increasing.18-21 
Medicine can be provided by different healthcare providers - trained or untrained. In some cases, self-
medication is also practiced, which can be either appropriate or problematic. When the usage of multiple 
drugs is evidence-based and optimized, it improves patient’s health outcomes including life expectancy 
and quality of life (QoL). This is considered as appropriate polypharmacy. In many cases, polypharmacy 
is the most obvious therapeutic option. However, on many occasions, especially when the use of 
multiple drugs is not based on evidence, it can lead to interactions between drugs and results in adverse 
drug events (ADEs).6,22 This is known as problematic polypharmacy. According to a recently published 
study, 1% of all hospital admissions are caused by drug-drug interactions, and appropriate medication 
can prevent such interactions.23 The risk of ADEs is 13% when two drugs are used; and increases to 
58% and 82% when five drugs and seven or more drugs are used, respectively.24 ADEs are mainly of 
two types: adverse drug reactions and adverse drug effects. These two types are inter-related. Adverse 
drug reactions are detected by their clinical manifestations (symptoms and/or signs). Adverse drug 
effects are usually detected by laboratory tests (e.g. biochemical) or by clinical investigations (e.g. 
endoscopy).14 Problematic polypharmacy can have a negative effect on the patient, their family/carer, 
the health system, and the economy. In patients, it can adversely affect their health outcomes (including 
life expectancy and QoL) and their compliance with medicines.25-27 Many high-income countries have 
published guidance and other tools on polypharmacy (and on deprescribing). For example, the UK’s 
National Institute for Health and Care Excellence (NICE) has published a document summarizing the 
evidence-base on this key therapeutic topic, which has been identified to support medicines 
optimization.28  
The scenario in South Asia 
The current territories of eight countries namely, Afghanistan, Bangladesh, Bhutan, India, Maldives, 
Nepal, Pakistan, and Sri Lanka from South Asia.29 Despite various diversities, these countries are 
grouped together due to their common geographical location, socio-cultural and ethical traits.30 One-
third of the world’s total population lives in South Asia.29 Like the rest of the world, the dual burden of 
diseases is high in this region.2 A recently published systematic review reported that the prevalence of 
multimorbidity (of chronic diseases) in South Asia ranged widely from around 5% to 83%, with the most 
common chronic diseases being hypertension, arthritis, diabetes, cardiac problems and skin diseases.29 
In South Asia, a diverse range of healthcare providers works in rural and urban areas. Generally, 
modern medicine (allopathy), as well as traditional medicine practitioners, are considered as medical 
professionals in South Asia. A registered traditional medicine practitioner undergoes the formal training 
programme, similar to modern medicine practitioners. There are unqualified practitioners as well. All 
these practitioners prescribe different types of medicines, and many times without any scientific 
evidence base.30 In South Asia, modern and traditional medicines are used simultaneously by many 
people. In addition, self-medication is widely practiced for preventing and managing illnesses.31 Some 
of the reasons behind self-medication are poor accessibility, availability, and affordability of quality 
healthcare as well as easy availability of many drugs over-the-counter.32 Thus, the usage of multiple 
drugs, many times without any evidence, leads to inappropriate polypharmacy in South Asia.31,33-37    
The rationale for the systematic review 
Several studies have been conducted in South Asia on incidence, prevalence, risk factors and health 
consequences of polypharmacy among adults.30,33-46 A preliminary search was conducted in MEDLINE, 
EMBASE, CINAHL, PsycINFO, BNI, Web of Science, Scopus and AMED and until now, no systematic 
review has been conducted on this topic. This summarized information will help to inform local, national, 
regional and international health experts to fully understand the issue and draw attention to further plans 
for necessary action, such as developing and implementing guidelines and tools to support medicines 
optimization (and deprescribing).  
Keywords 
Polypharmacy, incidence, prevalence, risk factors, health consequences, South Asia 
Inclusion criteria 
Population  
The review will include studies conducted among adults (aged ≥18 years) in the general population or 
in any disease-specific group and residing in any country within South Asia (i.e., Afghanistan, 
Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, and Sri Lanka). Any setting will be eligible, 
including community, residential care, primary care, secondary care, and tertiary care.  
Condition 
We will include any health condition. In research studies on polypharmacy, authors will exclude complex 
and severe conditions where management requires multiple medicines (thus, we will follow the authors’ 
reported opinion in this regard). 
The review will include studies on polypharmacy, where polypharmacy is defined as 
simultaneous usage of multiple regular medicines (as defined by the respective authors of the included 
studies). This will include, but not limited to, prescribed medicines and over-the-counter medicines, both 
western and traditional medicines (we will follow the authors’ reported opinion in this regard). We 
anticipate that data on polypharmacy will be reported via participant-reported methods or case/medical 
notes and prescriptions.  
Outcome/exposure  
Question 1: Incidence/prevalence of polypharmacy 
 This review question will include studies reporting the incidence/prevalence of polypharmacy. 
Question 2: Risk factors of polypharmacy 
This review question will include studies that report the risk factors of polypharmacy as the exposure 
and the incidence/prevalence of polypharmacy as the outcome. Risk factors of polypharmacy will 
include, but not limited to, non-modifiable factors (e.g., age, sex, ethnicity), lifestyle factors (e.g., 
smoking, alcohol intake, diet, physical activity, weight), environmental factors (e.g., occupation, 
housing, water and sanitation), and health conditions (e.g., cardiovascular diseases, mental health 
disorders, cancer, endocrine disorders).  
Question 3: Health consequences of polypharmacy 
The review question will include studies that report the incidence/prevalence of polypharmacy as the 
exposure and the health consequences of polypharmacy as the outcome. Health consequences as an 
outcome of polypharmacy will include, but not limited to, hospital related outcomes (e.g., admissions, 
readmissions, length of stay assessed at short (<30 days), medium (30-90 days) or long term (>90days) 
time points) and any negative clinical outcomes (e.g., drug effects - immediate and delayed, mortality 
and morbidity). 
Study design  
The incidence/prevalence of polypharmacy review question will include the following epidemiological 
study designs: cross-sectional, prospective cohort and longitudinal. The risk factors and health 
consequences of polypharmacy review questions will include the following epidemiological study 
designs: comparative case-control, cross-sectional, cohort and longitudinal.  
Methods  
The systematic review process will follow the preferred reporting items for systematic reviews and meta-
analyses (PRISMA) and Joanna Briggs Institute (JBI) systematic review methodology guidelines.47-52  
Search strategy 
An initial limited search was carried out in MEDLINE and EMBASE databases using the initial keywords, 
and these keywords were polypharmacy and South Asia. The titles and abstracts of the studies were 
screened for keywords, and the index terms used to describe the article were also identified. The search 
results were inspected to ensure that the relevant articles were identified. 
We aim to search for a wide range of sources, to find both published and unpublished studies. The 
following, databases will be searched from their dates of inception: MEDLINE, EMBASE, CINAHL, 
PsycINFO, BNI, Web of Science, Scopus and AMED. No date or language restrictions will be applied, 
and translations will be sought where necessary. The search strategy, to be used in MEDLINE, is 
detailed in Appendix I. This search strategy will be adopted for other databases, in consultation with an 
information specialist/librarian. The search for unpublished studies will include EthOS, OpenGrey, 
ProQuest Dissertations, and Theses. The reference list of all the identified reviews and studies selected 
for inclusion in the review will be screened for additional studies. 
Study selection  
Following the search, all identified citations will be collated and uploaded into Endnote 8.2 (Clarivate 
Analytics, PA, USA), a reference management software, and duplicates will be removed.53 Titles and 
abstracts will be screened for eligibility using the inclusion criteria by two reviewers independently (NK 
and KC/JLB). Studies identified as potentially eligible or those without an abstract will have their full-
text retrieved and their details will be imported into the JBI's premier software for systematic review of 
the literature, a system for the unified management, assessment, and review of information (JBI 
SUMARI).52 Full-text of the studies will be assessed against the inclusion criteria by two reviewers 
independently (NK and KC/JLB). Full-text studies that do not meet the inclusion criteria will be excluded, 
and the reasons for exclusion will be reported. Any disagreements that arise between the two reviewers 
will be resolved through discussion. If consensus is not reached, then a third reviewer (KC/JLB) will be 
involved. Although one search strategy will be used to answer three separate research questions posed, 
it should be noted that studies will be selected for each of these questions and three separate PRISMA 
flowcharts will be used for reporting purpose. 
Assessment of methodological quality 
Included studies will be critically assessed, independently, by two reviewers (NK and KC/JLB) using the 
standardized critical appraisal tools incorporated within JBI SUMARI, as appropriate to the study 
design.47-55 All studies, regardless of the results of their methodological quality, will undergo data 
extraction and synthesis, where possible. As recommended by JBI, a cut-off score will not be used to 
include/exclude studies as most of the studies are likely to be of poor quality. 52 Apart from high-quality 
studies, poor quality studies can also generate potentially valuable insights. Together, they can lead to 
a richer understanding of the research phenomenon.  
Data extraction 
Data will be extracted from papers included in the review using the standardized data extraction tool 
incorporated within JBI SUMARI,47-52,54-55 independently by two reviewers (NK and KC/JLB). Any 
disagreements that arise between the two reviewers will be resolved through discussion. If consensus 
is not reached, then a third reviewer (KC/JLB) will be involved. The data extracted will include specific 
details about the epidemiological study design, definition of polypharmacy (including details like 
prescribed medicine, over-the-counter medicine, western medicine, traditional medicine), country, 
population (e.g., age, sex, general population/disease-specific group), setting (e.g., community, 
residential care, primary care, secondary care, tertiary care), inclusion and exclusion criteria, sample 
size, data collection procedure and tool (e.g., participant-reported method, case/medical note, 
prescription), data analysis and incidence/prevalence of polypharmacy, risk factors of polypharmacy 
and health consequences of polypharmacy, depending on the review question.  
Where possible, we will attempt to differentiate between problematic and appropriate polypharmacy 
and the types of medications (prescribed medicines and over-the-counter medicines, both western and 
traditional medicines) being used. We will follow the authors’ reported opinion in this regard. 
 
Data synthesis 
We will initially use a narrative synthesis approach to look systematically at the data and to describe 
each study based on the three separate review questions. Patterns in the data will be identified through 
tabulation of results, and content analysis using an inductive approach (where the concepts are derived 
from the data) will be used to translate the data to identify areas of commonality between the studies.52 
We will assess the reasons for differences in the magnitude of the outcomes for polypharmacy practice 
through investigating within-study differences (including different settings and different population 
groups) and between study differences (including study design, age groups, gender and definition of 
polypharmacy).   
Question 1: Incidence/prevalence of polypharmacy  
Where possible, for each study, we will calculate raw proportions using the number of events divided 
by the total number of people in the study to estimate the incidence/prevalence of polypharmacy 
practice. Variances of the raw proportions will be stabilized using the Freeman-Tukey variant of the 
arcsine square root transformation to bound 95% confidence intervals (CIs) between 0 and 1.56 Where 
possible, we will perform random effects meta-analysis to estimate pooled incidence/prevalence with 
95% CIs to allow for heterogeneity resulting from inherent biases within the different study designs.  
Question 2: Risk factors of polypharmacy 
Where possible, for each study, we will extract estimates of risk with 95% CIs. Adjusted estimates will 
be used in preference to crude estimates. Where only raw data is presented, we will use this to estimate 
either odds ratios for case-control studies or risk ratios for other study designs. Odds ratios and risk 
ratios will be pooled together and reported as pooled relative risks (RR) with 95% CIs using random-
effects meta-analysis models. For exposures reported in categories or as quantiles, we will use the 
most exposed group compared to the least exposed. 
Question 3: Health consequences of polypharmacy  
Where possible, for each study, we will extract estimates of risk with 95% CIs. Adjusted estimates will 
be used in preference to crude estimates. Where only raw data is presented, we will use this to estimate 
either odds ratios for case-control studies or risk ratio for other study designs. Odds ratios and risk 
ratios will be pooled together and reported as pooled RR with 95% CIs using random-effects meta-
analysis models. For exposure reported in categories, we will use the most exposed group compared 
to the least exposed.   
Investigations of heterogeneity and reporting biases 
For all the three reviews, we will quantify and explore heterogeneity using the methods described below. 
Heterogeneity will be quantified using I2.54 Data permitting, we will explore reasons for heterogeneity 
using subgroup analyses based on age (65+ years only versus 18+ years), gender, 
problematic/appropriate polypharmacy, types of medications, specific disease groupings, country and 
healthcare setting. Also, where data permit, we will conduct sensitivity analyses by excluding poor 
methodological quality studies to assess the robustness of the conclusions. Statistical analysis will be 
performed using JBI SUMARI and Stata 15.54,57 Where there are at least 10 studies in the meta-
analysis, we will assess for the presence of publication bias using funnel plots. 
 Assessing certainty in the findings 
A modified version of the Grading of Recommendations, Assessment, Development and Evaluation 
(GRADE) method will be used to determine the strength of evidence for each finding related to the 
categorization of risk factors,58 and reported within a summary of findings table. Due to the observational 
nature of the study designs included in this review, findings will be initially ranked as low and will be 
downgraded to very low if there is evidence of any of the following - 1. Risk of bias, 2. Imprecision, 3. 
Inconsistency of evidence, 4. Indirectness, 5. Publication Bias. We will upgrade further based on the 
magnitude of association, evidence of a dose-response relationship, and where residual confounding 
would increase the magnitude of the effect. We will follow the below-mentioned summary (Table 1) to 
evaluate the quality of evidence:   
Insert Table 1 
Three reviewers (NK, KC and JLB) will be involved in this process. 
Conflict of interest 
The authors declare no conflict of interest. 
 
Funding 
NK is a Ph.D. student, funded by the Government of Bangladesh.  
 
Acknowledgments 
The authors would like to thank JG, a senior research librarian, for her contribution to the search 
strategy. 
 
 
 
References 
1. Islam S, Rahman F, Siddiqui M. Bangladesh is experiencing double burden with infectious 
diseases and non-communicable diseases (NCD's): an issue of emerging epidemics. AKMMC 
J. 2014;5(1):46-50. 
2. Basnyat B, Rajapaksa LC. Cardiovascular and infectious diseases in South Asia: the double 
whammy. BMJ. 2004;328(7443):781. 
3. Rachel N. Chronic diseases in developing countries: health and economic burdens. Ann N Y 
Acad Sci. 2008;1136:70-9. 
4. NCD mortality and morbidity [Internet]. World Health Organization. 2018 [cited 2018 January 
2]. Available from: http://www.who.int/gho/ncd/mortality_morbidity/en/. 
5. Adair T. Progress towards reducing premature mortality. Lancet Glob Health. 2018;6(12) 
6. Afshar S, Roderick PJ, Kowal P, Dimitrov BD, Hill AG. Multimorbidity and the inequalities of 
global aging: a cross-sectional study of 28 countries using the World Health Surveys. BMC 
Public Health. 2015;15:776. 
7. Abe J, Umetsu R, Uranishi H, Suzuki H, Nishibata Y, Kato Y, et al. Analysis of polypharmacy 
effects in older patients using Japanese Adverse Drug Event Report database. PLoS One. 
2017;12(12).e0190102. 
8. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic 
review of definitions. BMC Geriatrics. 2017;17(1):230. 
9. Mortazavi S, Shati M, Keshtkar A, Malakauti SK, Bazargan M, Assari S. Defining polypharmacy 
in the elderly: a systematic review protocol. BMJ Open. 2016;6(3).e010989. 
10. Pappa E, Kontodimopoulos N, Papadopoulos A, Tountas Y, Niakas D. Prescribed-drug 
utilization and polypharmacy in a general population in Greece: association with 
sociodemographic, health needs, health-services utilization, and lifestyle factors. Eur J Clin 
Pharmacol. 2010;67(2):185-92. 
11. Alzner R, Bauer U, Pitzer S, Schreier MM, Osterbrink J, Iglseder B. Polypharmacy, potentially 
inappropriate medication and cognitive status in Austrian nursing home residents: results from 
the OSiA study. Wien Med Wochenschr. 2016;166(5-6):161-5. 
12. Loya A, González-Stuart A, Rivera J. Prevalence of polypharmacy, polyherbacy, nutritional 
supplement use and potential product interactions among older adults living on the United 
States-Mexico border. Drugs Aging. 2009;26(5):423-36. 
13. Nascimento R, Álvares J, Guerra Junior AA, Gomes IC, Silveria MR, Costa EA, et al. 
Polypharmacy: a challenge for the primary health care of the Brazilian Unified Health System. 
Rev Saude Publica. 2017;51(suppl 2).19s. 
14. Charlesworth CJ, Smit E, Lee DSH, Alramadhan F, Odden MC.  Polypharmacy among adults 
aged 65 years and older in the United States: 1988–2010. J Gerontol A Biol Sci Med Sci. 
2015;70:989–95. 
15. Payne R, Avery A, Duerden M, Saunders CL, Simpson CR, Abel GA. Prevalence of 
polypharmacy in a Scottish primary care population. Eur J Clin Pharmacol. 2014;70(5):575-81. 
16. Dhalwani N, Fahami R, Sathanapally H, Seidu S, Davies MJ, Khunti K. Association between 
polypharmacy and falls in older adults: a longitudinal study from England. BMJ Open. 
2017;7(10).e016358. 
17. Kim H, Shin JY, Kim MH, Park BJ. Prevalence and predictors of polypharmacy among Korean 
elderly. PLoS One. 2014;9(6). 
18. Kantor E, Rehm C, Haas J, Chan AT, Giovannucci EL. Trends in prescription drug use among 
adults in the United States from 1999-2012. Am J Med. 2015;1818:314-7. 
19. Aronson JK. Polypharmacy, appropriate and inappropriate. Br J Gen Pract. 2006;56(528):484-
5. 
20. Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy 
and drug-drug interactions: population database analysis 1995–2010. BMC Med. 2015;13:74. 
21. Junius-Walker U, Theile G, Hummers-Pradier E. Prevalence and predictors of polypharmacy 
among older primary care patients in Germany. Fam Pract. 2007;24(1):14–9. 
22. Gnjidic D, Le Couteur D, Kouladjian L, Hilmer SN. Deprescribing trials: methods to reduce 
polypharmacy and the impact on prescribing and clinical outcomes. Clin Geriatr Med. 
2012;28(2):237-53. 
23. Ayvaz S, Horn J, Hassanzadeh O, Zhu Q, Stan J, Talonetti NP, et al.  Towards a complete 
dataset of drug-drug interaction information from publicly available sources. J Biomed Inform. 
2015;55(206):17.  
24. Fulton MM, Allen ER.  Polypharmacy in the elderly: a literature review. J Am Acad Nurse 
Pract. 2005;17(4):123-32. 
25. Abolhassani N, Castioni J, Marques V, Peter V, Gerard W. Determinants of change in 
polypharmacy status in Switzerland: the population-based CoLaus study. Eur J Clin 
Pharmacol. 2017; 73(9):1187-94. 
26. Riker G, Setter S. Polypharmacy in older adults at home: what it is and what to do about it--
implications for home healthcare and hospice. Home Healthc Nurse. 2012;30(8):474-85. 
27. Rollason V, Vogt N. Reduction of polypharmacy in the elderly. Drugs Aging. 2003;20(11):817-
32. 
28. Multimorbidity and polypharmacy [Internet]. National Institute for Health and Care Excellence. 
2018 [cited 2018 February 2]. Available from: 
https://www.nice.org.uk/advice/ktt18/resources/multimorbidity-and-polypharmacy-pdf-
58757959453381.  
29. Asia and the Pacific [Internet]. United Nations. 2018 [cited 2018 February 10]. Available from: 
http://www.un.org/en/sections/where-we-work/asia-and-pacific.  
30. Sarwar KN, Cliff P, Saravanan P, Kunti K, Nirantharakumar K, Narendran P. Comorbidities, 
complications and mortality in people of South Asian ethnicity with type 1 diabetes compared 
with other ethnic groups: a systematic review. BMJ Open. 2017;7.e015005. 
31. Pati S, Swain S, Hussain MA, Akker M, Metsemakers J, Knottnerus JA, et al. Prevalence and 
outcomes of multimorbidity in South Asia: a systematic review. BMJ Open. 2015;5.e007235. 
32. Khandeparkar A, Rataboli PV. A study of harmful drug-drug interactions due to polypharmacy 
in hospitalized patients in Goa Medical College. Perspect Clin Res. 2017;8(4):180-6. 
33. Wijesinghe PR, Jayakody RL,Seneviratne R. Prevalence and predictors of self-medication in a 
selected urban and rural district of Sri Lanka. WHO South East Asia J Public health. 
2012;1(1):28-41. 
34. Ahmed SM, Islam QS. Availability and rational use of drugs in primary healthcare facilities 
following the national drug policy of 1982: is Bangladesh on right track? J Health Popul Nutr. 
2012;30(1):99-108. 
35. Sabzwari SR, Qidwai W, Bhanji S. Polypharmacy in elderly: a cautious trail to tread. J Pak Med 
Assoc. 2013;63(5):624-7. 
36. Keyes LE, Mather L, Duke C, Regmi N, Phelan B, Pant S, Starling J, et al. Older age, chronic 
medical conditions and polypharmacy in Himalayan trekkers in Nepal: an epidemiologic survey 
and case series. J Travel Med. 2016;23(6). 
37. Rasu RS, Iqbal M, Hanifi S, Moula A, Hoque S, Rasheed S, et al. Level, pattern, and 
determinants of polypharmacy and inappropriate use of medications by village doctors in a rural 
area of Bangladesh. Clinicoecon Outcomes Res. 2014;3(6):515-21. 
38. Mazhar F, Akram S, Malhi SM, Haider N. A prevalence study of potentially inappropriate 
medications use in hospitalized Pakistani elderly. Aging Clin Exp Res. 2018; 30(1):53-60. 
39. Koshy B, Gopal Das CM, Rajashekarachar Y, Bharathi DR, Hosur SS. A cross-sectional 
comparative study on the assessment of quality of life in psychiatric patients under remission 
treated with monotherapy and polypharmacy. Indian J Psychiatry. 2017;59(3):333-40. 
40. Rakesh KB, Chowta MN, Shenoy AK, Shastry R, Pai SB. Evaluation of polypharmacy and 
appropriateness of prescription in geriatric patients: a cross-sectional study at a tertiary care 
hospital. Indian J Pharmacol. 2017;49(1):16-20. 
41. Salwe KJ, Kalyansundaram D, Bahurupi Y. A study on polypharmacy and potential drug-drug 
interactions among elderly patients admitted in department of medicine of a tertiary care 
hospital in Puducherry. J Clin Diagn Res. 2016;10(2). 
42. Joshua L, Devi P, Guido S. Adverse drug reactions in medical intensive care unit of a tertiary 
care hospital. Pharmacoepidemiol Drug Saf. 2009;18(7):639-45. 
43. Rambhade S, Chakarborty A, Shrivastava A, Patil UK, Rambhade A. A survey 
on polypharmacy and use of inappropriate medications. Toxicol Int. 2012;19(1):68-73.  
44. Sehgal V, Bajwa SJ, Sehgal R, Bajaj A, Khaira U, Kresse V.Polypharmacy and potentially 
inappropriate medication use as the precipitating factor in readmissions to the hospital. J Family 
Med Prim Care. 2013;2(2):194-9. 
45. Ahmed B, Nanji K, Mujeeb R, Patel MJ. Effects of polypharmacy on adverse drug reactions 
among a prospective cohort study. PLoS One. 2014;9(11):e112133. 
46. Patel T, Bhabhor P, Desai N, Shah S, Patel P, Vatsala E, et al. Adverse drug reactions in a 
psychiatric department of tertiary care teaching hospital in India: analysis of spontaneously 
reported cases.  Asian J Psychiatr. 2015;17:42-9 
47. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) [Internet]. 
PRISMA. 2015 [cited 2018 February 27]. Available from: http://prisma-
statement.org/prismastatement/Checklist.aspx.  
48. Joanna Briggs Institute reviewer's manual [Internet]. Joanna Briggs Institute. 2017 [cited 2017 
January 1]. Available from: https://reviewersmanual.joannabriggs.org/. 
49. Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic 
reviews of observational epidemiological studies reporting prevalence and cumulative 
incidence data. Int J Evid Based Healthc. 2015;13(3):147–53.  
50. Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Chapter 5: Systematic reviews of prevalence 
and incidence. In: Aromataris E, Munn Z, editors. Joanna Briggs Institute Reviewer's Manual 
[Internet]. Adelaide (AU): The Joanna Briggs Institute, 2017. [cited 2018 May 1]. Available 
from: https://reviewersmanual.joannabriggs.org/. 
51. Moola S, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R, et al. Chapter 7: Systematic 
reviews of etiology and risk. In: Aromataris E, Munn Z, editors. Joanna Briggs Institute 
reviewer's manual [Internet]. Adelaide (AU): Joanna Briggs Institute. 2017. [cited 2017 March 
30]. Available from: https://reviewersmanual.joannabriggs.org/. 
52. Lockwood C, Porritt K, Munn Z, Rittenmeyer L, Salmond S, Bjerrum M, et al. Chapter 2: 
systematic reviews of qualitative evidence. In: Aromataris E, Munn Z, editors. Joanna Briggs 
Institute Reviewer's Manual [Internet]. Adelaide (AU): The Joanna Briggs Institute, 2017. [cited 
2018 Apr 24. Available from : https://reviewersmanual.joannabriggs.org/ 
53. Endnote 8.2. Clarivate Analytics, PA, USA [Internet]. Endnote. 2017 [cited 2018 March 5]. 
Available from: http://endnote.com. 
54. Joanna Briggs Institute system for the unified management, assessment and review of 
information (JBI SUMARI) [Internet]. Joanna Briggs Institute. 2017 [cited 2018 March 6]. 
Available from: https://www.jbisumari.org/.  
55. Elo S, Kyngäs H. The qualitative content analysis process.J Adv Nurs. 2008;62(1):107-15.  
56. Freeman-Tukey (square root and arcsine) transforms [Internet]. StatsRef. 2014 [cited 2018 
March 18]. Available from: http://www.statsref.com/HTML/index.html? freeman-tukey.html.  
57. Stata statistical software: release 15. College Station, TX [Internet]. StataCorp LLC. 2017 [cited 
2018 March 10]. Available from: https://www.stata.com/company/.  
58. Grading of recommendations assessment, development and evaluation (GRADE) [Internet]. 
GRADE. 2004 [cited 2018 March 20]. Available from: http://www.gradeworkinggroup.org/.  
 
 
Appendix I 
Search strategy 
1. exp Polypharmacy/ 
2. Polypham*.mp. [mp=title, abstract, original title, the name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier, synonyms] 
3. Polymedication or poly-medication.mp. 
4. Polymedicine or poly-medicine.mp 
5. Polydrug* or poly-drug* 
6. Multipharm*.mp. [mp=title, abstract, original title, the name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, 
rare disease supplementary concept word, unique identifier, synonyms] 
7. Multiple drugs or multiple-drugs.mp. 
8. Multiple medications or multiple-medications.mp. 
9. Multimedicat* or Multi-medicat* 
10. Multidrug* or multi-drug*  
11. Overprescrib* 
12. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11  
13. South Asia*.mp. or South Asia/ 
14. Afghanistan*.mp. or Afghanistan/ 
15. Bangladesh*.mp. or Bangladesh/  
16. Bhutan*.mp. or Bhutan/  
17. India*.mp. or India/ 
18. Maldives*.mp. or Maldives/ 
19. Nepal*.mp. or Nepal/ 
20. Pakistan*.mp. or Pakistan/ 
21.  Sri Lanka*.mp. or Sri Lanka/ 
22. 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21  
23. 12 and 22 
Table 1: Measurement of quality of evidence using GRADE method 
 
Certainty What it means 
Very Low The true effect is markedly different from the 
estimated effect 
Low The true effect might be markedly different from 
the estimated effect 
Moderate The authors believe that the true effect is 
probably close to the estimated effect 
High The authors have a lot of confidence that the true 
effect is similar to the estimated effect 
 
